Laura J. Esserman

Active 1983–2025

Also published as
LAURA J. ESSERMAN
211
Papers
27,968
Citations
90
h-index
195
i10-index

Citations

Citations per year for Laura J. Esserman1982: 1 citations1984: 3 citations1985: 4 citations1986: 2 citations1987: 2 citations1988: 1 citations1989: 1 citations1991: 2 citations1992: 6 citations1993: 5 citations1994: 2 citations1995: 3 citations1996: 5 citations1997: 6 citations1998: 3 citations1999: 11 citations2000: 20 citations2001: 12 citations2002: 21 citations2003: 31 citations2004: 43 citations2005: 45 citations2006: 71 citations2007: 107 citations2008: 131 citations2009: 124 citations2010: 160 citations2011: 156 citations2012: 178 citations2013: 247 citations2014: 306 citations2015: 286 citations2016: 267 citations2017: 328 citations2018: 270 citations2019: 814 citations2020: 976 citations2021: 999 citations2022: 762 citations2023: 698 citations2024: 1,153 citations2025: 593 citations2026: 26 citations1983: no citations, so this year is not shown1990: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,529 citing papers, 28.7% of this breakdownChina: 1,077 citing papers, 8.8% of this breakdownUnited Kingdom: 885 citing papers, 7.2% of this breakdownItaly: 615 citing papers, 5% of this breakdownGermany: 522 citing papers, 4.3% of this breakdownCanada: 463 citing papers, 3.8% of this breakdownFrance: 435 citing papers, 3.5% of this breakdownSpain: 383 citing papers, 3.1% of this breakdownNetherlands: 370 citing papers, 3% of this breakdownAustralia: 368 citing papers, 3% of this breakdownBelgium: 273 citing papers, 2.2% of this breakdownSweden: 242 citing papers, 2% of this breakdown
0%28.7%Other 25.4%

Fields

  • Medicine46.6%
  • Biochemistry, Genetics and Molecular Biology41.9%
  • Immunology and Microbiology4.2%
  • Computer Science2.5%
  • Health Professions1%
  • Engineering0.8%
  • Other3%

Topics

  • Breast Cancer Treatment Studies9.5%
  • Cancer Genomics and Diagnostics4.1%
  • Cancer Immunotherapy and Biomarkers3.5%
  • Breast Lesions and Carcinomas3.3%
  • Radiomics and Machine Learning in Medical Imaging3%
  • Cancer Cells and Metastasis2.9%
  • Other73.7%

Coauthors

All papers

Open in search
  1. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2020 cited by 438

  2. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Richard B. Schwab, W. Fraser Symmans, Laura van ‘t Veer, Douglas Yee, Angela DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Donald A. Berry, Laura J. Esserman - JAMA Oncology 2020 cited by 706

  3. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gillian L. Hirst, Laura J. Esserman, Laura van ‘t Veer - Cancer Cell 2022 cited by 326

  4. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Scott Berry, Ashish Sanil, Adam L. Asare, Jeffrey B. Matthews, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Douglas Yee, Laura J. van’t Veer, Nola M. Hylton, Angela DeMichele, Donald A. Berry, Laura J. Esserman - Cancer Cell 2021 cited by 330

  5. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laura van ‘t Veer - Cancer Cell 2023 cited by 171

  6. Personalized early detection and prevention of breast cancer: ENVISION consensus statement

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Devilee, Suzette Delaloge, Marjanka K. Schmidt, Martin Widschwendter - Nature Reviews Clinical Oncology 2020 cited by 439

  7. Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Erica Stringer-Reasor, Anne M. Wallace, Lajos Pusztai, Judy C. Boughey, Erin D. Ellis, Anthony Elias, Janice Lu, Julie E. Lang, Hyo S. Han, Amy S. Clark, Rita Nanda, Donald W. Northfelt, Qamar J. Khan, Rebecca K. Viscusi, David Euhus, Kirsten K. Edmiston, Jane Yuet Ching Hui, Kathleen Kemmer, John W. Park, Minetta C. Liu, Olufunmilayo I. Olopade, Brian Leyland‐Jones, Debasish Tripathy, Stacy L. Moulder, Hope S. Rugo, Richard B. Schwab, Shelly S. Lo, Teresa Helsten, Heather Beckwith, Patricia Haugen, Nola M. Hylton, Laura J. van’t Veer, Jane Perlmutter, Michelle Melisko, Amy Wilson, Garry Peterson, Adam L. Asare, Meredith Buxton, Melissa Paoloni, Julia L. Clennell, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Jeffrey B. Matthews, Smita Asare, Ashish Sanil, Scott Berry, Laura J. Esserman, Donald A. Berry - JAMA Oncology 2020 cited by 225

  8. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kelly K. Hunt - Journal of Clinical Oncology 2017 cited by 411

  9. Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study

    Authors: , , , , , , , , , , , , , , , , , , , - Radiology 2023 cited by 87

  10. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Charlotte Proudhon, Denise M. Wolf, Jessica B. Bauldry, Elin Borgen, Rin Nagaoka, Vicente Carañana, Jaco Kraan, Marisa Maestro, Sara Y. Brucker, Karsten E. Weber, Fabien Reyal, Dominic Amara, Mandar Karhade, Randi R. Mathiesen, H. Tokiniwa, Antonio Llombart‐Cussac, Alessandra Meddis, Paul Blanche, Koenraad D’Hollander, Paul Cottu, John W. Park, Sibylle Loibl, Aurélien Latouche, Jean‐Yves Pierga, Klaus Pantel - JNCI Journal of the National Cancer Institute 2018 cited by 282

  11. Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barbara Haley, Rita Nanda, Donald W. Northfelt, Debasish Tripathy, William C. Wood, Cheryl A. Ewing, Richard B. Schwab, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Donald A. Berry, Laura J. Esserman - New England Journal of Medicine 2016 cited by 555

  12. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL

    Authors: , , , , , , , , , , , , , , , - Radiology 2015 cited by 277

  13. Guiding principles for the responsible development of artificial intelligence tools for healthcare

    Authors: , , - Communications Medicine 2023 cited by 76

  14. Leukocyte composition of human breast cancer

    Authors: , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2011 cited by 473

  15. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial

    Authors: , , , , , , , , , , , , , , , , , , , - Radiology 2018 cited by 284

  16. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial

    Authors: , , , , , , , , , - JNCI Journal of the National Cancer Institute 2016 cited by 246

  17. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2006 cited by 1,320

  18. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kathy S. Albain, Rashmi K. Murthy, Judy C. Boughey, Minetta C. Liu, Barbara Haley, Anthony Elias, Amy S. Clark, Kathleen Kemmer, Claudine Isaacs, Julie E. Lang, Hyo S. Han, Kirsten K. Edmiston, Rebecca K. Viscusi, Donald W. Northfelt, Qamar J. Khan, Brian Leyland‐Jones, Sara J. Venters, Sonal Shad, Jeffrey B. Matthews, Smita Asare, Meredith Buxton, Adam L. Asare, Hope S. Rugo, Richard B. Schwab, Teresa Helsten, Nola M. Hylton, Laura van ‘t Veer, Jane Perlmutter, Angela DeMichele, Douglas Yee, Donald A. Berry, Laura J. Esserman - JAMA Oncology 2021 cited by 106

  19. Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2011 cited by 560

  20. Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL

    Authors: , , , , , , , , , , , , - Radiology 2012 cited by 489

  21. The WISDOM Study: breaking the deadlock in the breast cancer screening debate

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elad Ziv - npj Breast Cancer 2017 cited by 280

  22. Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 75

  23. The Integration of Clinical Trials With the Practice of Medicine

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Steven R. Cummings, Gregory Curfman, Laura J. Esserman, Lee A. Fleisher, Joseph B. Franklin, Ralph Gonzalez, Cynthia Grossman, Tufia C. Haddad, Roy S. Herbst, Adrian F. Hernandez, Diane Holder, Leora Horn, Grant D. Huang, Alison J. Huang, Nancy Kass, Rohan Khera, Walter J. Koroshetz, Harlan M. Krumholz, Martin Landray, Roger Lewis, Tracy A. Lieu, Preeti Malani, Christa Lese Martin, Mark McClellan, Mary Mcdermott, Stephanie R. Morain, Susan A. Murphy, Stuart G. Nicholls, Stephen J. Nicholls, Peter J. O’Dwyer, Bhakti K. Patel, Eric C. Peterson, Sheila A. Prindiville, Joseph S. Ross, Kathy Rowan, Gordon D. Rubenfeld, Christopher Seymour, Rod S Taylor, Joanne Waldstreicher, Tracy Y. Wang - JAMA 2024 cited by 70

  24. Whole-genome analysis informs breast cancer response to aromatase inhibition

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julie A. Margenthaler, Gildy V. Babiera, P. Kelly Marcom, J. Michael Guenther, Marilyn Leitch, Kelly K. Hunt, John A. Olson, Tao Yu, Christopher A. Maher, Lucinda Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L. Vickery, Adnan Elhammali, Helen Piwnica‐Worms, Sandra McDonald, Mark A. Watson, David J. Dooling, David M. Ota, Li-Wei Chang, Ron Bose, Timothy J. Ley, David Piwnica‐Worms, Joshua M. Stuart, Richard K. Wilson, Elaine R. Mardis - Nature 2012 cited by 1,035